Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs VICI Properties Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while VICI Properties Inc trades at $26.29 (market cap $28.94B). The key difference: VICI Properties Inc is far larger — about 3.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and VICI Properties Inc pays a 6.85% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | VICI | |
|---|---|---|
Market Cap | $8.04B | $28.94B |
Sector | Health | Real Estate |
52-Week High | $339.75 | $33.93 |
52-Week Low | $241.71 | $25.94 |
Enterprise Value | $7.85B | $46.16B |
Dividend Yield | — | 6.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
VICI Properties trades at $26.40, up 1.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The REIT shows strong fundamentals with a P/E of 9, net income margin of 76.83%, and consistent cash flow generation. Recent news highlights its 6.8% dividend yield and investment-grade balance sheet, though concerns linger over tenant concentration with Caesars and MGM accounting for 70% of rent.
The outlook remains positive with a consensus price target of $30.75 implying 16.5% upside, supported by 20 buy ratings. Risks include Las Vegas market exposure and potential lease uncertainties from tenant buyouts, but the stock's discounted valuation and secure dividend profile offer a compelling case for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
